Clinical Report: Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

Overview

The DE-CART trial evaluates the safety and efficacy of adaptive stereotactic body radiation therapy (SBRT) for men with intermediate- or high-risk prostate cancer. Participants receive treatment every other day over a total of five sessions, with follow-up assessments to monitor side effects and overall wellbeing.

Background

Prostate cancer remains a significant health concern, particularly in men with intermediate- and high-risk disease. Adaptive SBRT represents a promising treatment modality that may enhance therapeutic outcomes while minimizing toxicity. Understanding its safety profile is crucial for optimizing patient management in this population.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• Adaptive SBRT is administered in five treatment sessions over 2-3 weeks.
• Inclusion criteria focus on histologically confirmed intermediate- and high-risk prostate cancer.
• Follow-up includes assessments at 90 days and every 3-6 months thereafter.
• Exclusion criteria include prior pelvic radiation therapy and significant comorbidities.
• Adaptive SBRT aims to reduce organ-at-risk dose and treatment-related toxicity.

Clinical Implications

Healthcare professionals should consider adaptive SBRT as a viable treatment option for patients with intermediate- or high-risk prostate cancer. Ongoing monitoring of side effects and overall health is essential to ensure patient safety and treatment efficacy.

Conclusion

The DE-CART trial highlights the potential of adaptive SBRT in managing prostate cancer, emphasizing the need for further research to validate its safety and effectiveness in clinical practice.

References

1. The ASCO Post, 2024 -- High-Risk Localized Prostate Cancer: Survival Benefit With Long-Term ADT and Dose-Escalated Radiation Therapy
2. The ASCO Post, 2015 -- Androgen-Deprivation Therapy Added to Radiation Therapy Improves Disease Control in Intermediate-Risk Prostate Cancer
3. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, 2025
4. The ASCO Post — High-Risk Localized Prostate Cancer: Survival Benefit With Long-Term ADT and Dose-Escalated Radiation Therapy
5. The ASCO Post — Novel Decision-Making Tool for Androgen-Deprivation Therapy for Patients With Prostate Cancer
6. Shorter radiation improves patient experience but not disease control for intermediate-risk prostate cancer - ASTRO
7. Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial
8. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf